Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

Maurer, Marcus; Rosén, Karin; Hsieh, Hsin-Ju; S. Saini, Sarbjit; Grattan, Clive; M. Giménez‐Arnau, Ana; Agarwal, Sunil; L. Doyle, Ramona; Canvin, Janice; P. Kaplan, Allen; B. Casale, Thomas

doi:10.1056/nejmoa1215372

Public

Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

Published in New England Journal of Medicine • Feb 24, 2013

Authors:

Marcus Maurer

Karin Rosén

Hsin-Ju Hsieh

Abstract

BACKGROUND: Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-antihistamines, even at high doses. In phase 2 trials, omalizumab, an anti-IgE monoclonal antibody [corrected] that targets IgE and affects mast-cell and b...

Subject

Medicine

Omalizumab

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!